

PRESS RELEASE  
January 18, 2021



## **An van Es Johansson resigns as board director in BioInvent International AB**

**Lund, Sweden – January 18, 2021** – BioInvent International AB (publ) today announced that An van Es Johansson will resign as a director of the board effective as of 15 February 2021. She has served as a director of the board since 2016. The resignation is due to personal reasons. She will continue to advise BioInvent as an independent advisor.

### **About BioInvent**

BioInvent International AB (OMXS: BINV) is a clinical stage company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapies, with four programs in clinical development. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.

The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at [www.bioinvent.com](http://www.bioinvent.com).

### **For further information, please contact:**

Martin Welschof, CEO  
+46 (0)46 286 85 50  
[martin.welschof@bioinvent.com](mailto:martin.welschof@bioinvent.com)

Mary-Ann Chang, LifeSci Advisors  
+44 7483 284853  
[mchang@lifesciadvisors.com](mailto:mchang@lifesciadvisors.com)

### **BioInvent International AB (publ)**

Co. Reg. No. Org nr: 556537-7263  
Visiting address: Sölvegatan 41  
Mailing address: 223 70 LUND  
Phone: +46 (0)46 286 85 50  
[www.bioinvent.com](http://www.bioinvent.com)

